Titan Pharmaceuticals, Inc. Stock News

MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Titan (NASDAQ: TTNP) for possible breaches of fiduciary duty and other violations of law in its transaction with KE Sdn. Bhd. Click here to learn how to join our investigation https://www.ademilaw.com/case/titan-pharmaceuticals-inc or call Guri Ademi toll-free at 866-264-3995.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) and KE Sdn. Bhd. is fair to Titan shareholders. Upon closing of the proposed transaction, Titan shareholders expect to own approximately 13.3% of the combined company. Halper Sadeh encourages Titan shareholders to click here to learn more ab...

NEW YORK, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan”) today announced that it has entered into a Merger and Contribution and Share Exchange Agreement (the “Merger Agreement”) regarding a business combination with KE Sdn. Bhd. (“KE”). The Merger Agreement was approved by Titan's board of directors (the “Board”). If the Merger Agreement is approved by th...